Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association

Michael Miller, Neil J. Stone, Christie Ballantyne, Vera Bittner, Michael H. Criqui, Henry N. Ginsberg, Anne Carol Goldberg, William James Howard, Marc S. Jacobson, Penny M. Kris-Etherton, Terry A. Lennie, Moshe Levi, Theodore Mazzone, Subramanian Pennathur

Research output: Contribution to journalArticle

1000 Citations (Scopus)

Abstract

This scientific statement reviews the pivotal role of triglycerides in lipid metabolism and reaffirms that triglyceride is not directly atherogenic but represents an important biomarker of CVD risk because of its association with atherogenic remnant particles and apo CIII. Although some familial disorders of triglyceride metabolism are associated with increased risk for pancreatitis when fasting triglyceride level exceeds 1000 mg/dL, others are associated with increased atherosclerotic risk. Moreover, IR, obesity, and sedentary lifestyle can all lead to or aggravate metabolic syndrome risk factors, which should urgently prompt clinicians to focus first on improving the patient's lifestyle. Knowledge of the metabolic pathways of triglyceride-rich particles and the consequences of hypertriglyceridemia is crucial in understanding the characteristic lipid alterations in DM, lipodystrophic disorders including those seen with HIV, and chronic renal disease. Measurements of non-HDL-C, apo B, or both may be especially useful in those with prominent triglyceride/ HDL abnormalities in which LDL-C measurements may underestimate true atherosclerotic vascular risk.

Original languageEnglish (US)
Pages (from-to)2292-2333
Number of pages42
JournalCirculation
Volume123
Issue number20
DOIs
StatePublished - May 24 2011

Fingerprint

Triglycerides
Cardiovascular Diseases
Sedentary Lifestyle
Hypertriglyceridemia
Apolipoproteins B
Metabolic Networks and Pathways
Chronic Renal Insufficiency
Lipid Metabolism
Pancreatitis
Blood Vessels
Life Style
Fasting
Obesity
Biomarkers
HIV
Lipids

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., ... Pennathur, S. (2011). Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 123(20), 2292-2333. https://doi.org/10.1161/CIR.0b013e3182160726
Miller, Michael ; Stone, Neil J. ; Ballantyne, Christie ; Bittner, Vera ; Criqui, Michael H. ; Ginsberg, Henry N. ; Goldberg, Anne Carol ; Howard, William James ; Jacobson, Marc S. ; Kris-Etherton, Penny M. ; Lennie, Terry A. ; Levi, Moshe ; Mazzone, Theodore ; Pennathur, Subramanian. / Triglycerides and cardiovascular disease : A scientific statement from the American Heart Association. In: Circulation. 2011 ; Vol. 123, No. 20. pp. 2292-2333.
@article{6c17fda2ab624f74b9c49b037ddf5c4d,
title = "Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association",
abstract = "This scientific statement reviews the pivotal role of triglycerides in lipid metabolism and reaffirms that triglyceride is not directly atherogenic but represents an important biomarker of CVD risk because of its association with atherogenic remnant particles and apo CIII. Although some familial disorders of triglyceride metabolism are associated with increased risk for pancreatitis when fasting triglyceride level exceeds 1000 mg/dL, others are associated with increased atherosclerotic risk. Moreover, IR, obesity, and sedentary lifestyle can all lead to or aggravate metabolic syndrome risk factors, which should urgently prompt clinicians to focus first on improving the patient's lifestyle. Knowledge of the metabolic pathways of triglyceride-rich particles and the consequences of hypertriglyceridemia is crucial in understanding the characteristic lipid alterations in DM, lipodystrophic disorders including those seen with HIV, and chronic renal disease. Measurements of non-HDL-C, apo B, or both may be especially useful in those with prominent triglyceride/ HDL abnormalities in which LDL-C measurements may underestimate true atherosclerotic vascular risk.",
author = "Michael Miller and Stone, {Neil J.} and Christie Ballantyne and Vera Bittner and Criqui, {Michael H.} and Ginsberg, {Henry N.} and Goldberg, {Anne Carol} and Howard, {William James} and Jacobson, {Marc S.} and Kris-Etherton, {Penny M.} and Lennie, {Terry A.} and Moshe Levi and Theodore Mazzone and Subramanian Pennathur",
year = "2011",
month = "5",
day = "24",
doi = "10.1161/CIR.0b013e3182160726",
language = "English (US)",
volume = "123",
pages = "2292--2333",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "20",

}

Miller, M, Stone, NJ, Ballantyne, C, Bittner, V, Criqui, MH, Ginsberg, HN, Goldberg, AC, Howard, WJ, Jacobson, MS, Kris-Etherton, PM, Lennie, TA, Levi, M, Mazzone, T & Pennathur, S 2011, 'Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association', Circulation, vol. 123, no. 20, pp. 2292-2333. https://doi.org/10.1161/CIR.0b013e3182160726

Triglycerides and cardiovascular disease : A scientific statement from the American Heart Association. / Miller, Michael; Stone, Neil J.; Ballantyne, Christie; Bittner, Vera; Criqui, Michael H.; Ginsberg, Henry N.; Goldberg, Anne Carol; Howard, William James; Jacobson, Marc S.; Kris-Etherton, Penny M.; Lennie, Terry A.; Levi, Moshe; Mazzone, Theodore; Pennathur, Subramanian.

In: Circulation, Vol. 123, No. 20, 24.05.2011, p. 2292-2333.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Triglycerides and cardiovascular disease

T2 - A scientific statement from the American Heart Association

AU - Miller, Michael

AU - Stone, Neil J.

AU - Ballantyne, Christie

AU - Bittner, Vera

AU - Criqui, Michael H.

AU - Ginsberg, Henry N.

AU - Goldberg, Anne Carol

AU - Howard, William James

AU - Jacobson, Marc S.

AU - Kris-Etherton, Penny M.

AU - Lennie, Terry A.

AU - Levi, Moshe

AU - Mazzone, Theodore

AU - Pennathur, Subramanian

PY - 2011/5/24

Y1 - 2011/5/24

N2 - This scientific statement reviews the pivotal role of triglycerides in lipid metabolism and reaffirms that triglyceride is not directly atherogenic but represents an important biomarker of CVD risk because of its association with atherogenic remnant particles and apo CIII. Although some familial disorders of triglyceride metabolism are associated with increased risk for pancreatitis when fasting triglyceride level exceeds 1000 mg/dL, others are associated with increased atherosclerotic risk. Moreover, IR, obesity, and sedentary lifestyle can all lead to or aggravate metabolic syndrome risk factors, which should urgently prompt clinicians to focus first on improving the patient's lifestyle. Knowledge of the metabolic pathways of triglyceride-rich particles and the consequences of hypertriglyceridemia is crucial in understanding the characteristic lipid alterations in DM, lipodystrophic disorders including those seen with HIV, and chronic renal disease. Measurements of non-HDL-C, apo B, or both may be especially useful in those with prominent triglyceride/ HDL abnormalities in which LDL-C measurements may underestimate true atherosclerotic vascular risk.

AB - This scientific statement reviews the pivotal role of triglycerides in lipid metabolism and reaffirms that triglyceride is not directly atherogenic but represents an important biomarker of CVD risk because of its association with atherogenic remnant particles and apo CIII. Although some familial disorders of triglyceride metabolism are associated with increased risk for pancreatitis when fasting triglyceride level exceeds 1000 mg/dL, others are associated with increased atherosclerotic risk. Moreover, IR, obesity, and sedentary lifestyle can all lead to or aggravate metabolic syndrome risk factors, which should urgently prompt clinicians to focus first on improving the patient's lifestyle. Knowledge of the metabolic pathways of triglyceride-rich particles and the consequences of hypertriglyceridemia is crucial in understanding the characteristic lipid alterations in DM, lipodystrophic disorders including those seen with HIV, and chronic renal disease. Measurements of non-HDL-C, apo B, or both may be especially useful in those with prominent triglyceride/ HDL abnormalities in which LDL-C measurements may underestimate true atherosclerotic vascular risk.

UR - http://www.scopus.com/inward/record.url?scp=85027956925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027956925&partnerID=8YFLogxK

U2 - 10.1161/CIR.0b013e3182160726

DO - 10.1161/CIR.0b013e3182160726

M3 - Article

AN - SCOPUS:85027956925

VL - 123

SP - 2292

EP - 2333

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 20

ER -

Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN et al. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2011 May 24;123(20):2292-2333. https://doi.org/10.1161/CIR.0b013e3182160726